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actin, Flk-1, vascular endothelial growth factor (VEGF) and 
endothelial nitric oxide synthase (eNOS). ANOVA (Tukey’s 
test) and independent t test (p  ! 0.05) were used for com-
parison between BM and saline groups.  Results: Maternal 
BM injected on days 25–26 to pregnant rabbits induced a 
significant decrease in fetal body and lung weight and the 
lung-to-body weight ratio in the preterm pups shortly after 
injection. BM led to a dose-dependent thinning of the arte-
rial media and adventitia (pulmonary arteries with an exter-
nal diameter (ED) of  ! 100   m), to an increase in the percent-
age of non-muscularized peripheral vessels (ED  ! 60   m), in 
eNOS and VEGF immunoreactivity of the endothelial and 
smooth muscle cells in the pulmonary vessels and to an in-
crease in Flk-1-positive pulmonary epithelial cell density. 
 Conclusions: Maternal administration of BM caused thin-
ning of the arterial wall of pulmonary vessels (ED  ! 100   m) 
and a decrease in muscularization in peripheral vessels (ED 
 ! 60   m). This coincided with increased expression of Flk-1 
in the endothelium and smooth muscle cells of the pulmo-
nary arteries. All the effects studied were dose-dependent. 
 Copyright © 2007 S. Karger AG, Basel 
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 Abstract 
 Objectives: Glucocorticoids promote lung maturation and 
reduce the incidence of respiratory distress syndrome in pre-
mature newborns. We hypothesized that betamethasone 
(BM), which is known to induce thinning of the alveolar walls, 
would also thin the arterial media and adventitia of intra-
parenchymatic vessels in developing rabbit lungs.  Study De-
sign: 112 fetuses from 21 time-mated, pregnant, giant white 
rabbits received maternal injections of BM at either 0.05 or 
0.1 mg/kg/day on days 25–26 of gestational age. Controls 
received either saline (10 does, 56 fetuses) or no injection (10 
does, 59 fetuses). Fetuses were harvested from day 27 on-
wards until term (day 31). 44 additional fetuses (8 does) were 
harvested between days 23 and 26. Endpoints were wet 
lung-to-body weight ratio, vascular morphometric indices 
and immunohistochemistry staining for   -smooth muscle 
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 Introduction 
 Preterm delivery occurs in 7–10% of all pregnancies 
and remains a major cause of infant mortality and mor-
bidity mostly due to the consequences of respiratory dis-
tress syndrome and bronchopulmonary dysplasia. In 
neonatal pulmonary hypertension, the arteries fail to di-
late normally due to the immature pulmonary arterial 
smooth muscle cells, which are supposed to remodel, re-
lax and become thinner  [1] . Over the years, several trials 
have shown the beneficial effects of antenatal adminis-
tration of glucocorticoids (GC) by promoting lung matu-
ration and reducing the incidence of respiratory distress 
syndrome in premature newborns  [2] . GC increase sur-
factant pool size, decrease protein leak, increase air space 
and induce thinning of the alveolar walls, hence improv-
ing ventilatory measurements and gas exchange  [3] . How-
ever adverse effects have been reported, such as a decrease 
in fetal body, lung and liver weights as well as brain de-
velopment. Both effects seem to be dependent on the dose 
and timing of administration of steroids  [4, 5] . 
 We, as well as others, have used the rabbit as a model 
for fetal lung development in the study of different perina-
tal conditions  [6, 7] . To a certain extent the lung develop-
ment of rabbits mimics that of the human lung  [8] . At 
term, rabbit lungs are in the terminal stage of saccular 
morphology with alveolization starting already prior to 
birth. Of interest to experimental medicine, rabbit does 
have a short gestational period, a large litter size and are 
inexpensive. Administration of betamethasone (BM) to 
pregnant rabbit does was previously shown to increase 
surfactant proteins A and B in the fetal lung, to improve 
ventilatory function and gas exchange in parallel with 
dose-dependent fetal growth restriction and decrease in 
fetal lung weight  [3] . So far, the specific effects of antenatal 
GC on vascular morphology have not yet been studied. 
 Vascular endothelial growth factor (VEGF) is a potent 
vascular endothelial cell-specific mitogen, critical for de-
velopmental angio- and vasculogenesis, next to pneumo-
cyte proliferation and type-II alveolar epithelial cell dif-
ferentiation  [9, 10] . It further stimulates microvascular 
permeability and vasodilatation. Most of the effects of 
VEGF are induced through its two tyrosine kinase recep-
tors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR)  [11] . 
VEGF regulates endothelial nitric oxide synthase (eNOS) 
activity and expression  [12] in endothelial cell cultures, 
an effect mediated by activation of the Flk-1/KDR recep-
tor. Nitric oxide (NO) inhibits smooth muscle cell migra-
tion and activity of MMP-2, one of the zinc-dependent 
metalloproteases, which has been specifically implicated 
in smooth muscle cell migration. Dexamethasone was re-
cently shown to inhibit in vitro production and activity 
of MMP-2 both directly as well as through enhancing NO 
production  [13, 14] . 
 We aimed to determine the morphologic effects of ma-
ternal administration of a single course of BM (canalicu-
lar phase) on pulmonary vascular development using a 
morphometric and immunohistochemical approach. We 
hypothesized that GC, causing thinning of the alveolar 
walls, would have similar effects on the arterial media 
and adventitia of intra-parenchymal vessels and promote 
the vascular transition to extra-uterine life. 
 Material and Methods 
 Rabbits were housed at 17 days of gestation in separate cages 
at normal room temperature and normal daylight, with free ac-
cess to food and water. A total of 264 fetuses from 49 time-mated, 
pregnant, giant white rabbits were included in this experiment. 
Does and their fetuses were assigned to 2 BM (Celestone  , Scher-
ing-Plough, Brussels, Belgium) administration groups receiving 
either  0.05 mg/kg/day (BM = 0.05, 11 does, 62 fetuses) or 0.1 mg/
kg/day (BM = 0.1, 10 does, 50 fetuses) injected on days 25 and 26, 
with a 24-hour interval between  [3] . This corresponds to the can-
alicular stage of lung development. Control groups received either 
2 injections of placebo (0.9% NaCl 0.2 ml/day, 10 does, 50 fetuses) 
or were not injected (10 does, 58 fetuses). We aimed to have at least 
2 does for each different time point. The earlier stages of lung de-
velopment were determined in 8 does, carrying 44 fetuses that 
were harvested on days 23–26. Animals were treated according to 
current guidelines on animal well-being and the Ethics Commit-
tee for Animal Experimentation of the Faculty of Medicine of the 
Katholieke Universiteit Leuven approved the experiments. 
 Sacrifice and Tissue Processing 
 Does were euthanized with an intravenous bolus (1 ml/kg) of 
a mixture of embutramide 200 mg, mebezonium 50 mg and tet-
racaine hydrochloride 5 mg (T61  ; Hoechst Marion Roussel, 
Brussels, Belgium). Fetuses were delivered by cesarean section 20 
min later to ensure that all fetuses were dead and no respiration of 
air would take place. Macerated fetuses were recorded as non-sur-
vivors and excluded from further analysis. During necropsy, the 
fetus was weighed using a scale measuring accurately up to 0.001 
g (HF 2000; A&D Instruments, Haasrode, Belgium). The lungs 
were removed as a whole, separated from the trachea, and the right 
and left lungs were weighed. The right lung was snap frozen in 
liquid nitrogen and stored at –80  °  C for later biochemical and mo-
lecular studies, which are not the subject of this report. The left 
lung was immersed in 6% neutral buffered formalin solution for 
24 h. After fixation, all left lungs were embedded in paraffin, cut 
into 5-  m mid-sagittal sections through the entire lung  [15] for 
further histological and immunohistochemical staining. For vas-
cular morphometry the slides were stained with Elastica van Gie-
son (Hart’s method). The air space-tissue fraction was evaluated 
on hematoxyline-eosine-stained slides by the point-counting 
method and was used to correct the density of cells  [16] . 
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 Immunohistochemical Procedures 
 Briefly, after deparaffinization, endogenous peroxidase block-
ing (methanol with 0.3% H 2 O 2 ; 30 min) and rinsing with phos-
phate-buffered saline (PBS; 0.01  M , pH 7.3), microwave heat re-
trieval was performed, followed by rinsing in PBS. For   -smooth 
muscle actin (  -SMA) no heat retrieval was required. After pre-
incubation for 30 min with 10% normal goat serum (X0907 Da-
koCytomation, Glostrup, Denmark), the slides were incubated 
with mouse anti-human monoclonal anti-  -SMA (M0851, Dako-
Cytomation; 1:  100, 30 min), or with mouse anti-human monoclo-
nal anti-eNOS (610296 Transduction Laboratories, Lexington, 
Ky., USA; 1:  25, 2 h), or with mouse anti-human monoclonal anti-
VEGF (MS-350-P1, NeoMarkers, Calif., USA; 1:  50, 1 h), or with 
mouse anti-human monoclonal anti-Flk-1 (sc-6251, Santa Cruz 
Biotechnology, Calif., USA; 1:  50, 30 min). After rinsing, the slides 
stained for   -SMA were incubated with goat anti-mouse biotin-
labelled IgG (E0354, DakoCytomation; 1:  400, 30 min), rinsed 
again and incubated with AB complex/HRP (K0355, DakoCyto-
mation; 30 min). The slides stained for eNOS, VEGF and Flk-1 
were incubated with peroxidase-conjugated EnVision TM  + reagent 
(K4001, DakoCytomation; 30 min). Then all slides were rinsed 
with PBS, incubated with peroxidase substrate solution contain-
ing DAB (K3468, DakoCytomation, 10 min), rinsed with distilled 
water, counterstained with hematoxylin, dehydrated and mount-
ed. Negative controls for specificity consisted of the omission of 
the primary antibody. 
 Gross Anatomy 
 Fetal body weight (FBW) and total wet fetal lung weight (TLW) 
enabled calculation of the lung-to-body weight ratio (LBWR). 
 Microscopic Parameters 
 In non-overlapping fields up to 50 peripheral vessels with an 
external diameter (ED) of  ^  100   m were measured, which cor-
respond to the pre- and intra-acinar arteries in rabbit lungs and 
are believed to be the resistance arteries  [17] . All diameters were 
measured at a magnification of  ! 200 along the shortest axis of 
the vessel  [18] with a Zeiss Axioplan light microscope (Carl Zeiss, 
Oberkochen, Germany). 
 Vascular morphometric parameters include adventitial diam-
eter (AD,   m); ED (  m); internal diameter (ID,   m). From these 
the following variables can be calculated: proportionate medial 
thickness (%MT = (ED – ID)/ED  ! 100) and proportionate ad-
ventitial thickness (%AT = (AD – ED)/ED  ! 100). The latter two 
parameters are proportionate values, nullifying the effects of va-
sodilatation, vasoconstriction and fixation on measurements as 
shown earlier by several authors both in human and animal spec-
imens  [18, 19, 36] . 
 Muscularization of Pulmonary Vessels.  Semiquantitative iden-
tification of the presence of smooth muscle bundles in the arte-
rial and arteriolar wall was performed on slides stained for   -
SMA. For all vessels with an ED of  ^  100   m, the diameter was 
noted and whether it was positively or negatively   -SMA stained. 
The vessels were empirically categorized into 3 classes ( ^  30, 30–
60 and 60–100   m) in order to assess the extent of peripheral 
muscularization along the acinar and pre-acinar vessels, as de-
scribed previously  [7] . The percentages of muscularized vessels in 
intra-acinar ( ! 30   m) vessels and beyond (30–60 and 60–100 
  m) were calculated in all categories  [7, 17, 19] . 
 Density of Flk-1-Positive Cells and Immunoreactivity for VEGF 
and eNOS.  In 20 non-overlapping randomly selected fields, the 
Flk-1-positive alveolar epithelial cells were counted (magnifica-
tion  ! 400). This was limited to the air-exchanging parenchyma. 
The density of Flk-1-positive alveolar epithelial cells per square 
millimeter of tissue was recalculated. For Flk-1 immunoreactiv-
ity of the vascular smooth muscle and endothelial cells, and for 
VEGF and eNOS immunoreactivity of the lung tissue, semiquan-
titative analysis was performed using an arbitrary visual scale 
with grading score ranging from 0 to 4: grade 0 = no staining; 
grade 1 = focal staining, and grades 2, 3, and 4 = diffuse, weak, 
moderate and strong staining, respectively  [20, 21] . 
 Table 1. Time course of changes in LBWR, and density of Flk-1-positive alveolar epithelial cells in fetal rabbit lungs after maternal 
administration of betamethasone (mean  8 SEM) 
Day 23 Day 24 Day 25 Day 26 Day 27 Day 28 Day 29 Day 30 Day 31
Control n = 8 n = 12 n = 12 n = 12 n = 13 n = 10 n = 11 n = 14 n = 11
LBWR 0.02280.001 0.02780.000 0.03280.001 0.03080.000 0.03180.001 0.02880.002 0.02680.001 0.02780.001 0.02280.000
Flk-1 epithelial 9,5238600 10,3728741 8,5128554 6,8928721 5,7878412 5,9008459 4,8578358 4,5128285 3,9258311
Placebo n = 6 n = 14 n = 11 n = 12 n = 13
LBWR 0.03180.001 0.02980.001 0.02880.001 0.02280.001 0.01980.001
Flk-1 epithelial 6,2298586 6,0858431 5,3378345 4,9568358 4,2128314
BM = 0.05 n = 10 n = 12 n = 10 n = 13 n = 13
LBWR 0.02680.002 0.02580.001° 0.02680.001 0.02080.001 0.02080.001
Flk-1 epithelial 1,15308734° 5,5008395 7,3008678 6,4328636 5.1588427
BM = 0.1 n = 12 n = 10 n = 11 n = 6 n = 6
LBWR 0.02580.001* 0.02780.001 0.02580.001 0.02280.001 0.01880.000
Flk-1 epithelial 23,7428742* 19,1348785* 17,1348654* 12,5228732a 10,5178643*
LBWR = Lung-to-body weight ratio; Flk-1 epithelial = density of Flk-1-positive parenchymal epithelial cells.
Differences between * BM = 0.1 and placebo and between ° BM = 0.05 and placebo are considered significant at p < 0.05.
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 Statistical Analysis 
 Morphometric determinations were done by two observers 
(X.R. and AM.V.d.B.), who were blinded to the nature of the ex-
perimental procedure, and their observations were averaged. 
LBWR, morphometric measurements and derived calculations 
are presented as mean  8 standard error of the mean (SEM). A 
day-by-day analysis over the pregnancy and within treatment 
groups was done with analysis of variance for multiple compari-
sons (ANOVA, Tukey’s HSD test). The difference between BM 
groups and placebo at given time points was analyzed using inde-
pendent t tests. All comparisons were performed using the Statis-
tica 6.0 software (StatSoft, Inc., Tulsa, Okla., USA). Probability 
(p) values of  ! 0.05 were considered statistically significant. 
 Results 
 After administration of BM, there was a significant 
decrease in FBW (p = 0.003) on day 27 and an even more 
prominent decrease in TLW (day 27, p = 0.002; day 28, 
p = 0.001), so that LBWR was significantly lower on day 
27 for BM = 0.1 (p = 0.001) and on day 28 for BM = 0.05 
(p = 0.001;  table 1 ). 
 Changes in %MT and %AT demonstrate a progressive 
thinning of the vascular wall throughout normal gestation 
(days 23–31, p = 0.001;  fig. 1 a, b). Placebo fetuses showed 
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 Fig. 1. Time course of changes in proportional medial thickness ( a ), proportional adventitial thickness ( b ),
percentage of small (ED  ! 30   m,  c ) and intermediate (ED = 30–60   m,  d ) muscularized pulmonary vessels 
after maternal administration of BM. Differences between ° BM = 0.05 and placebo,  *  BM = 0.1 and placebo, 
and  #  BM = 0.05 and BM = 0.1  were considered significant at p  ! 0.05. 
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changes similar to controls. The effects of BM are dose-
dependent. Following exposure to BM = 0.1, the %MT 
dropped significantly below that of the placebo group (p = 
0.001), an effect which disappeared on day 30. For BM = 
0.05 the decrease was only significant on day 28 (p = 0.046; 
 fig. 1 a). BM caused a decrease in %AT, its effect lasting
longer after the higher dose (BM = 0.05: day 27, p = 0.001; 
BM = 0.1: day 27, p = 0.001; day 28, p = 0.03;  fig. 1 b). 
 In control fetuses, the number of smaller (ED  ! 30   m) 
muscularized vessels decreased between days 23 and 28 
(p = 0.02) to remain unchanged later on. BM exerts a 
dose-dependent effect on the muscularization of small 
(ED  ! 30   m) and intermediate (ED = 30–60   m) sized 
vessels ( fig. 2 a, b), the effect of BM = 0.1 (day 27, p = 0.001; 
day 28, p = 0.001; day 29, p = 0.001; day 30, p = 0.01) be-
ing more prominent and lasting longer than after BM = 
0.05 (day 27, p = 0.001; day 29, p = 0.04;  fig. 1 c, d). 
 BM = 0.05 induced a 2-fold increase in Flk-1-positive 
alveolar epithelial cell density on day 27 (p = 0.001), 
whereas BM = 0.1 caused a 4-fold increase on days 27–28 
(p = 10 –6 , p = 0.0003) and a 2-fold increase until term (day 
29, p = 0.001; day 30, p = 0.001; day 31, p = 0.003;  table 1 ; 
 fig. 2 c, d,  4 e, f). There was also increased Flk-1 immuno-
reactivity of the vascular endothelial cells ( fig. 3 a,  4 a, b; 
p = 0.002), bronchial epithelial cells ( fig. 3 b; p = 0.001) 
and vascular smooth muscle cells ( fig. 3 c,  4 a–d; p = 0.001) 
in a dose-dependent fashion. Further, BM increased the 
VEGF ( fig. 2 e, f,  3 d; p = 0.002) and eNOS ( fig. 2 g, h,  3 e; 
p = 0.001) expression as well; this effect also being dose-
dependent. 
 Fig. 2. Fetal lung parenchyma (day 27), immunohistochemical 
sections counterstained with hematoxylin. Typical view of   -
SMA ( a ,  b ), Flk-1 ( c ,  d ), VEGF ( e ,  f ) and eNOS ( g ,  h ) staining of 
lung parenchyma in BM = 0.1 and placebo group, respectively. 
Alv = Alveole; iav = intra-acinar vessels (ED  ! 30   m); pav = pre-
acinar vessels (ED = 30–60   m); MB = membrane bronchioles; 
ep = pulmonary epithelial cells; end = pulmonary vascular endo-
thelial cells. Magnification  ! 640. Scale bar = 10   m. 
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 Fig. 3. Time course of changes in immunostaining grade of Flk-1 in endothelial cells ( a ), bronchial epithelium 
( b ), vascular smooth muscle cells ( c ) and VEGF ( d ) and eNOS ( e ) in the total lung tissue after maternal admin-
istration of BM. Differences between ° BM = 0.05 and placebo,  *  BM = 0.1 and placebo,  #  BM = 0.05 and BM = 
0.1 were considered significant at p  ! 0.05. 
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 Discussion 
 Antenatal GC have been clinically used for several de-
cades to enhance lung maturity, but they may reduce 
birth and lung weight  [22] . GC reduce placental size, 
hence also fetal growth, potentially by decreasing IGF-II 
mRNA levels in junctional zones of the placenta  [23] . 
This effect has been observed in fetal lambs  [24] as well 
as rabbits  [3] . A dose-effect relationship on lung and body 
weight has also been described earlier  [2] . It is possible 
that the administered steroids mediate their effect on wet 
lung weight through decreased lung liquid production 
and/or reabsorption of lung liquid, as earlier documented 
in humans and rabbits  [25, 37] . In the experiments of Ta-
bor et al.  [3] , doses of 0.01, 0.03 and 0.1 mg/kg were com-
pared, with the highest dose showing the most obvious 
effects. In our own experiments doses of 0.05 and 0.1 mg/
kg/day were used without any effect on LBWR in term 
pups, but decreased LBWR when evaluated within 2 days 
after administration. 
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 Fig. 4. Immunohistochemical staining for Flk-1 in intermediate pulmonary vessels (ED = 30–60   m,  a ,  b ), in 
large pulmonary vessels (ED = 60–100   m,  c ,  d ) and in the parenchyma ( e ,  f ) of a fetal rabbit lung (day 27) af-
ter maternal administration of BM = 0.1 or placebo, respectively. Alv. = Alveole; end = pulmonary  vascular 
endothelial cells; smc = vascular smooth muscle cells; br.ep = bronchial epithelial cells; alv.ep = alveolar epi-
thelial cells. Magnification  ! 640 (with use of a frame 768  ! 512 pixels). Scale bar = 10   m. 
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 Adaptation to extra-uterine life requires a rapid in-
crease in smooth muscle cell length and surface to in-
crease pulmonary vessel lumen diameter and lower their 
resistance  [26] . In persistent pulmonary hypertension of 
the newborn, pulmonary vasculature fails to relax at 
birth  [1] . This is believed to be due to an immaturity in 
physiologic vascular remodeling. In clinical practice an 
improvement in cardiovascular adaptation is observed in 
premature neonates, who received antenatal GC  [27] . 
Our work was mainly dedicated to the study of the time 
course of changes in peripheral lung vasculature follow-
ing antenatal GC administration. We used an experi-
mental model and morphometric techniques to docu-
ment vascular thinning shortly after injection of BM in 
doses adapted to this model. Morphologically, the most 
important components of the media and adventitia are 
fibroblasts and smooth muscle cells. During angiogenesis 
in the pseudoglandular and canalicular stages, bronchial 
smooth muscle cells migrate and line up around the ar-
teries. Later on, fibroblasts also migrate from the mesen-
chyme, line up around the arterial wall and develop 
smooth muscle cell phenotype  [28] . Okoye et al.  [29] ear-
lier observed medial and adventitial thinning as well as a 
decrease in the percentage of muscularized intra-acinar 
blood vessels following antenatal administration of 0.25 
mg/kg dexamethasone. This study, however, was in ni-
trofen-exposed rats that had congenital diaphragmatic 
hernias, and unfortunately no data on control fetuses (i.e. 
olive oil exposed) that received either saline or dexameth-
asone were included in the report  [29] . The lungs of sub-
jects with congenital diaphragmatic hernias are typically 
hypoplastic and show vascular changes on morphology. 
 In our study normally developing fetuses were ex-
posed to BM, however also resulting in decreased medial 
and adventitial thickness. The proportion of muscular-
ized small (ED  ! 30   m) and intermediate (ED = 30–60 
  m) pulmonary arteries was decreased after BM admin-
istration as well. The observed effects were dose-depen-
dent, i.e. more prominent and longer-lasting after the 
higher dose of BM = 0.1. Our study, its outcome variables 
and the methods used do not allow a direct explanation, 
so we can only speculate on the nature of our observa-
tions. Thinning of the media may be explained through 
inhibition of proliferation and migration of smooth mus-
cle cells and/or fibroblasts. In vitro, dexamethasone has 
been shown to downregulate DNA synthesis, prolifera-
tion and chemotactic activity of human fetal lung fibro-
blasts in a dose-dependent fashion  [30] . Dexamethasone 
further directly inhibits thrombin-stimulated prolifera-
tion of human airway smooth muscle cells  [31] as well as 
proliferation, DNA synthesis  [32] and migration of rat 
and human aortic smooth muscle cells in culture condi-
tions  [14] . 
 VEGF is a potent vascular endothelial cell-specific 
mitogen. It stimulates angiogenesis, microvascular per-
meability, and causes vasodilatation. VEGF has been 
shown to induce release of NO from rabbit and human 
vascular endothelial cells  [33] and to regulate eNOS ex-
pression  [34] . Increased eNOS expression in neonatal 
rat lungs is also mediated by Flk-1 receptor activation. 
In fetal lambs, VEGF inhibition impaired endothelium-
dependent vasodilatation, decreased eNOS expression 
and increased muscularization of small pulmonary ar-
teries  [35] . In our experiment, maternal administration 
of  BM increased Flk-1-positive cell density in the alveo-
lar parenchyma and Flk-1 immunoreactivity in vascular 
endothelial and smooth muscle cells. Immunoreactivity 
 to VEGF and eNOS was also increased by BM adminis-
tration. This makes a second, VEGF-dependent path-
way for BM-induced suppression of smooth muscle cell, 
fibroblast proliferation and migration possible, if not 
likely. 
 Almost no data on the effects of GC on pulmonary 
vasculature have been published. In summary, we have 
shown that antenatal administration of BM on days 25–
26 decreases the number of small muscularized intra-ac-
inar vessels and leads to a medial and adventitial thin-
ning of this category of vessels in normal rabbits by term. 
This suggests that antenatal steroid therapy may have a 
specific inhibitory effect on the developmental prolifera-
tion of the smooth muscle within the media of pulmo-
nary arteries. Taking into account that GC induce an in-
creased immunoreactivity for eNOS, VEGF and Flk-1, we 
can also suggest that antenatal GC may accelerate the 
normal process of medial wall attenuation in the pulmo-
nary arteries, which usually occurs soon after birth. Our 
findings indicate that prenatal GC may reduce the risk of 
pulmonary hypertension developing in the lungs of pre-
mature neonates. 
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